Anzeige
Anzeige
Anzeige

The multi-functionality of CD40L and its receptor CD40 in atherosclerosis

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH09-01-0029
Issue: 2009: 102/2 (Aug) pp. 183-420
Pages: 206-214

The multi-functionality of CD40L and its receptor CD40 in atherosclerosis

Dirk Lievens1; Wouter J. Eijgelaar1; Erik A. L. Biessen1; Mat J. A. P. Daemen1; Esther Lutgens1,2
1Experimental Vascular Pathology Division (EVP), Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM) University of Maastricht, The Netherlands; 2Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Aachen, Germany

Summary

Disrupting the CD40-CD40L co-stimulatory pathway reduces atherosclerosis and induces a stable atherosclerotic plaque phenotype that is low in inflammation and high in fibrosis. Therefore, inhibition of the CD40-CD40L pathway is an attractive therapeutic target to reduce clinical complications of atherosclerosis. The CD40-CD40L dyad is known to interact with other costimulatory molecules, to activate antigen-presenting cells (APC) and to contribute to T-cell priming and B-cell isotype switching. Besides their presence on T-cells and APCs, CD40 and CD40L are also present on macrophages, endothelial cells and vascular smooth muscle cells in the plaque, where they can exert pro-atherogenic functions. Moreover, recent progress indicates the involvement of neutrophil CD40, platelet CD40L and dendritic cell CD40 in atherogenesis. Since systemic CD40-CD40L modulation compromises host defense, more targeted interventions are needed to develop superior treatment strategies for atherosclerosis. We believe that by unravelling the cell-cell CD40-CD40L interactions, inhibition of cell-type specific (signalling components of) CD40(L) that do not compromise the patient’s immune system, will become possible. In this review, we highlight the cell-type specific multi-functionality of CD40-CD40L signalling in atherosclerosis.

Keywords

Atherosclerosis, inflammation, immunity, co-stimulation, TNF receptor- associated factor

DOI

http://dx.doi.org/10.1160/TH09-01-0029

You may also be interested in...

1.

P. Matusik (1), B. Guzik (1), C. Weber (2), T. J. Guzik (1)

Thromb Haemost 2012 108 3: 443-456

http://dx.doi.org/10.1160/TH12-05-0341

2.

D. F. J. Ketelhuth (1), G. K. Hansson (1)

Thromb Haemost 2011 106 5: 779-786

http://dx.doi.org/10.1160/TH11-05-0321

3.

Didier Hanriot1,2*, Gaëlle Bello1,2*, Armelle Ropars1,2, Carole Seguin-Devaux5, Gaël Poitevin1,2, Sandrine Grosjean3, Véronique Latger-Cannard2,3,4, Yvan Devaux1,2,5, Faiez Zannad1,2, Véronique Regnault2,4, Patrick Lacolley1,2, Paul-Michel Mertes1,2, Ketsia Hess*1,2, Dan Longrois*1,2

Thromb Haemost 2008 99 3: 558-569

http://dx.doi.org/10.1160/TH07-06-0410



Thrombosis News

Mobile technology identifies people with unknown atrial fibrillation at high risk of stroke – article published in Thrombosis and Haemostasis

The article “Feasibility and cost effectiveness of stroke prevention through community screening...

TH 111.4

The April 2014 TH 111.4 issue of Thrombosis and Haemostasis is a Theme Issue by Guest Editor B....

TH 111.3

Women with atrial fibrillation have a much higher risk for thromboembolic stroke than men suffering...